STAMFORD

SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference

Retrieved on: 
Wednesday, May 8, 2024
Bank of America, BofA Securities, Cancer, Therapy, Conference, Webcast, Event

STAMFORD, Conn., May 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the BofA Securities 2024 Health Care Conference, taking place in Las Vegas, Nevada on Tuesday, May 14, 2024 at 3:40 p.m. PT / 6:40 p.m.

Key Points: 
  • STAMFORD, Conn., May 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the BofA Securities 2024 Health Care Conference, taking place in Las Vegas, Nevada on Tuesday, May 14, 2024 at 3:40 p.m. PT / 6:40 p.m.
  • ET.
  • To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company’s website at https://ir.springworkstx.com .
  • A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.

Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024

Retrieved on: 
Monday, May 6, 2024
Therapy, Patient, Itch

STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will report first quarter 2024 financial results on Monday, May 13, 2024, after the U.S. markets close.

Key Points: 
  • STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will report first quarter 2024 financial results on Monday, May 13, 2024, after the U.S. markets close.
  • The press release will be available under “Press Releases” in the Investors section of the Company’s website at www.CaraTherapeutics.com .

Star Group, L.P. to Host Fiscal 2024 Second Quarter Webcast and Conference Call May 2, 2024

Retrieved on: 
Friday, April 26, 2024
Star, Special, SGU, Webcast

STAMFORD, Conn., April 26, 2024 (GLOBE NEWSWIRE) -- Star Group, L.P. (the “Company” or “Star”) (NYSE: SGU), a leading home energy distributor and services provider, today announced that it will release its fiscal 2024 second quarter results after the close of trading on May 1, 2024.

Key Points: 
  • STAMFORD, Conn., April 26, 2024 (GLOBE NEWSWIRE) -- Star Group, L.P. (the “Company” or “Star”) (NYSE: SGU), a leading home energy distributor and services provider, today announced that it will release its fiscal 2024 second quarter results after the close of trading on May 1, 2024.
  • Members of Star's management team will host a webcast and conference call at 11:00 a.m. Eastern Time the following day, May 2, 2024, to review the three months ended March 31, 2024.
  • The webcast will be accessible on the company’s website, at www.stargrouplp.com , and the telephone number for the conference call is 888-346-3470 (412-317-5169 for international callers).

SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Wednesday, April 24, 2024
Decentralized finance, FDA, Cancer, Mutation, Safety, NDA, Plantar fibromatosis, Food, Nirogacestat, MEK, ASCO, Patient, Society, APC, Adenomatous polyposis coli, Annual general meeting, Therapy, Pharmaceutical industry

STAMFORD, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that data from the Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) will be presented in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 31 to June 4, 2024. SpringWorks recently initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for mirdametinib in pediatric and adult patients with NF1-PN.

Key Points: 
  • STAMFORD, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that data from the Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) will be presented in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 31 to June 4, 2024.
  • SpringWorks recently initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for mirdametinib in pediatric and adult patients with NF1-PN.
  • Additional data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat) in adults with desmoid tumors were also accepted for presentation at ASCO, including an abstract describing the onset and resolution of ovarian toxicity for desmoid tumor patients treated with nirogacestat, as well as two additional sub-group analyses evaluating nirogacestat in desmoid tumor patients with poor prognostic factors and in those with adenomatous polyposis coli (APC) mutations.
  • “The Phase 2b ReNeu trial data are the cornerstone of our NDA for mirdametinib in NF1-PN, and we are very pleased that these data were accepted for an oral presentation at ASCO,” said Jim Cassidy, M.D., Ph.D., Chief Medical Officer of SpringWorks.

GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset

Retrieved on: 
Tuesday, April 23, 2024
Komodo, Congress, Partnership, WGS, Research, Life, Disease, GeneDx, Patient, Diagnosis, Standard of care, Clinical trial, Drug discovery, Medicine, Pharmaceutical industry

STAMFORD, Conn., April 23, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, a premier healthcare technology company for the pharmaceutical industry.

Key Points: 
  • STAMFORD, Conn., April 23, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, a premier healthcare technology company for the pharmaceutical industry.
  • The new partnership will increase access to GeneDx's extensive de-identified rare disease data set, now available through Komodo Health’s MapEnhance offering, including data from more than 500,000 exomes, enabling biopharma companies to access genetic insights that can help inform drug pipelines and accelerate clinical trial enrollment.
  • “The partnership between GeneDx and Komodo Health represents a milestone in advancing the understanding of rare disease and its associated drug development”, said Melanie Duquette, Chief Growth Officer, GeneDx.
  • GeneDx is continuing to showcase its value to biopharma companies through its participation in the World Orphan Drug Congress meeting in Boston, April 23-25th.

Star Group, L.P. Increases Quarterly Distribution to 17.25 Cents per Unit

Retrieved on: 
Thursday, April 18, 2024
The Company, Star, Special, SGU

STAMFORD, Conn., April 18, 2024 (GLOBE NEWSWIRE) -- Star Group, L.P. (the "Company" or "Star") (NYSE:SGU), a home energy distributor and services provider, today announced that it has increased its quarterly distribution for the three months ended March 31, 2024 to $0.1725 per common unit from $0.1625 per common unit.

Key Points: 
  • STAMFORD, Conn., April 18, 2024 (GLOBE NEWSWIRE) -- Star Group, L.P. (the "Company" or "Star") (NYSE:SGU), a home energy distributor and services provider, today announced that it has increased its quarterly distribution for the three months ended March 31, 2024 to $0.1725 per common unit from $0.1625 per common unit.

SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024

Retrieved on: 
Thursday, April 18, 2024
Cancer, Therapy, Webcast

on Thursday, May 2, 2024 to report its first quarter financial results and discuss recent business updates.

Key Points: 
  • on Thursday, May 2, 2024 to report its first quarter financial results and discuss recent business updates.
  • To join the live webcast and view the corresponding slides, please click here .
  • To access the live call by phone, please pre-register for the call by clicking here .
  • Once registration is complete, participants will be provided with a dial-in number and conference code to access the call.

The Lovesac Company Reports Fourth Quarter and Fiscal 2024 Financial Results

Retrieved on: 
Thursday, April 11, 2024
Investment, Advertising, Omnichannel, Transport, Tax, Comparable, Marketing, Growth, Wells Fargo

STAMFORD, Conn., April 11, 2024 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the home furnishing brand best known for its Sactionals, The World's Most Adaptable Couch, today announced financial results for the fourth quarter and fiscal 2024, which ended February 4, 2024.

Key Points: 
  • Gross profit increased $15.9 million, or 11.9%, to $149.6 million in the fourth quarter of fiscal 2024 from $133.7 million in the prior year period.
  • Operating income was $40.4 million in the fourth quarter of fiscal 2024 compared to $36.5 million in the prior year period.
  • During the fourth quarter of fiscal 2024 and 2023, the Company recorded an income tax expense of $10.2 million.
  • A conference call to discuss the financial results for the fourth quarter ended February 4, 2024 is scheduled for today, April 11, 2024, at 8:30 a.m. Eastern Time.

BPM Partners and BARC Join Forces to Deliver First of Its Kind Global CPM Priorities and Trends Research Report

Retrieved on: 
Wednesday, April 10, 2024
Research, Data, Research report, Benchmarking, Data collection, EPM, CPM, Pulse, BPM

This comprehensive document will combine data from two of the major surveys in this space: BPM Partners’ 2024 BPM Pulse and BARC’s The Planning Survey 24 .

Key Points: 
  • This comprehensive document will combine data from two of the major surveys in this space: BPM Partners’ 2024 BPM Pulse and BARC’s The Planning Survey 24 .
  • The BPM Partners team, led by founder and CEO Craig Schiff, and the BARC team, led by Dr. Christian Fuchs will analyze the data jointly.
  • This research report will deliver valuable guidance and benchmarking data for end user organizations planning their own performance management projects.
  • The jointly developed Global CPM Priorities and Trends research report is expected to be released this summer.

Benchmark at Stamford Assisted Living Community Named One of the Country's Best by U.S. News & World Report for Second Straight Year

Retrieved on: 
Wednesday, April 24, 2024
Alzheimer's disease, Housekeeping, Safety, News, Heart, Mind, Communication, Research, Transport, Dementia, Environment, Food, Empathy, Amnesia, Quality of life, Senior living, Nursing

STAMFORD, Conn., April 24, 2024 /PRNewswire-PRWeb/ -- Benchmark at Stamford, an assisted living and Mind & Memory Care community, has ranked among the best assisted living with memory care communities in Connecticut and the entire U.S. for the second straight year. In U.S. News & World Report's third annual Best Senior Living ratings published last week, the community was selected following a comprehensive resident and family member survey.

Key Points: 
  • STAMFORD, Conn., April 24, 2024 /PRNewswire-PRWeb/ -- Benchmark at Stamford , an assisted living and Mind & Memory Care community, has ranked among the best assisted living with memory care communities in Connecticut and the entire U.S. for the second straight year.
  • In U.S. News & World Report's third annual Best Senior Living ratings published last week, the community was selected following a comprehensive resident and family member survey.
  • -Julia Petrini, executive director, Benchmark at Stamford
    Benchmark at Stamford earned "Best" status by achieving the highest possible rating for assisted living.
  • For more information about Benchmark at Stamford, click here or go to its U.S. News profile at https://health.usnews.com/best-senior-living/benchmark-at-stamford-1877 .